These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38005269)

  • 1. Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide.
    Li Y; Eans SO; Ganno-Sherwood M; Eliasof A; Houghten RA; McLaughlin JP
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.
    Lowery JJ; Raymond TJ; Giuvelis D; Bidlack JM; Polt R; Bilsky EJ
    J Pharmacol Exp Ther; 2011 Mar; 336(3):767-78. PubMed ID: 21118955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
    Lei W; Vekariya RH; Ananthan S; Streicher JM
    J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
    Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
    J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Activity Relationships of a Novel Cyclic Hexapeptide That Exhibits Multifunctional Opioid Agonism and Produces Potent Antinociceptive Activity.
    Zhang Q; Xu B; Chen D; Wu S; Hu X; Zhang X; Yu B; Zhang S; Yang Z; Zhang M; Fang Q
    J Med Chem; 2024 Jan; 67(1):272-288. PubMed ID: 38118143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
    Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
    J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.
    Anand JP; Boyer BT; Mosberg HI; Jutkiewicz EM
    Psychopharmacology (Berl); 2016 Jul; 233(13):2479-87. PubMed ID: 27117141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
    Purington LC; Sobczyk-Kojiro K; Pogozheva ID; Traynor JR; Mosberg HI
    ACS Chem Biol; 2011 Dec; 6(12):1375-81. PubMed ID: 21958158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The search for opioid analgesics with limited tolerance liability.
    Wtorek K; Piekielna-Ciesielska J; Janecki T; Janecka A
    Peptides; 2020 Aug; 130():170331. PubMed ID: 32497566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
    Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
    Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-
    Yadlapalli JSK; Bommagani SB; Mahelona RD; Wan A; Gannon BM; Penthala NR; Dobretsov M; Crooks PA; Fantegrossi WE
    Pharmacol Res Perspect; 2018 Jul; 6(4):e00403. PubMed ID: 29930811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel Analgesics.
    McLaughlin JP; Rayala R; Bunnell AJ; Tantak MP; Eans SO; Nefzi K; Ganno ML; Dooley CT; Nefzi A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
    Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
    Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
    Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G
    Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
    Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
    J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities.
    Hu M; Giulianotti MA; McLaughlin JP; Shao J; Debevec G; Maida LE; Geer P; Cazares M; Misler J; Li L; Dooley C; Ganno ML; Eans SO; Mizrachi E; Santos RG; Yongye AB; Houghten RA; Yu Y
    Eur J Med Chem; 2015 Mar; 92():270-81. PubMed ID: 25559207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking.
    Dumitrascuta M; Bermudez M; Trovato O; De Neve J; Ballet S; Wolber G; Spetea M
    Molecules; 2021 May; 26(11):. PubMed ID: 34071603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactivity of new mu and delta opioid peptides.
    Capasso A
    Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
    Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
    Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.